ethyl (E)-2-fluoro-3-(4-chlorophenyl)propenoate | 26928-13-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: ethyl (E)-2-fluoro-3-(4-chlorophenyl)propenoate
• 英文别名: ethyl 2-fluoro-3-(4-chlorophenyl)-propenoate；cis-4-Chlor-α-fluor-zimtsaeure-ethylester；ethyl (E)-3-(4-chlorophenyl)-2-fluoroprop-2-enoate
• CAS: 26928-13-2
• 化学式: C₁₁H₁₀ClFO₂
• 分子量: 228.651
• InChiKey: FSIMPMVPCNFMPK-JXMROGBWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  氟碘乙酸乙酯 、 4-氯苯甲醛 在 四(三苯基膦)钯 、 三丁基砷 作用下， 反应 24.0h， 生成 ethyl (E)-2-fluoro-3-(4-chlorophenyl)propenoate 、 (Z)-3-(4-chloro-phenyl)-2-fluoro-acrylic acid ethyl ester
  参考文献：
  名称：

  A convenient palladium-catalyzed synthesis of α-fluoro-α,β-unsaturated esters

  摘要：

  During the treatment of ethyl alpha-fluoro-alpha-iodoacetate with aldehydes in the presence of tri-n-butylarsine and a catalytic amount (10 mol%) of Pd(PPh3)4, the aldehydes were eventually completely consumed and alpha-fluoro-alpha,beta-unsaturated esters were obtained in 52-90% yield.

  DOI：

  10.1016/s0022-1139(00)80109-8

文献信息

• P[N(<i>i-</i>Bu)CH₂CH₂]₃N: Nonionic Lewis Base for Promoting the Room-Temperature Synthesis of α,β-Unsaturated Esters, Fluorides, Ketones, and Nitriles Using Wadsworth−Emmons Phosphonates
  作者：Venkat Reddy Chintareddy、Arkady Ellern、John G. Verkade

  DOI：10.1021/jo1012515

  日期：2010.11.5

  serves as an effective promoter for the room-temperature stereoselective synthesis of α,β-unsaturated esters, fluorides, and nitriles from a wide array of aromatic, aliphatic, heterocyclic, and cyclic aldehydes and ketones, using a range of Wadsworth−Emmons (WE) phosphonates. Among the analogues of 1c [R = Me (1a), i-Pr (1b), Bn (1d)], 1a and 1b performed well, although longer reaction times were involved

  双环三氨基膦P（RNCH 2 CH 2）3 N（R = i -Bu，1c）可作为室温下立体选择性合成α，β-不饱和酯，氟化物和腈的有效促进剂芳香族，脂肪族，杂环和环状醛和酮，使用一系列Wadsworth-Emmons（WE）膦酸酯。在1c [R = Me（1a），i -Pr（1b），Bn（1d）]的类似物中，1a和1b表现良好，尽管涉及的反应时间更长，而1d导致的收率低于1c。氰基，氯，溴，甲氧基，氨基，酯和硝基等官能团的耐受性很好。我们能够分离和表征（通过X射线；见上文）由2b和1c形成的反应性WE中间体。
• Microwave-Assisted One-Pot Synthesis of α-Fluoro-α,β-Unsaturated Esters under Solvent-Free Conditions
  作者：Xiaochun Yu、Aishan Ren、Xiongjun Yang、Jing Hong

  DOI：10.1055/s-2008-1078213

  日期：——

  A microwave-assisted approach for the synthesis of α-fluoro-α,β-unsaturated esters from ethyl bromofluoroacetate, aldehydes, and triphenylphosphine in the presence of Zn-Cu under solvent-free conditions was achieved. The reaction was accomplished within five minutes with good product yields.

  实现了在无溶剂条件下，在 Zn-Cu 存在下，从溴氟乙酸乙酯、醛和三苯基膦合成 α-氟-α,β-不饱和酯的微波辅助方法。反应在五分钟内完成，产物收率良好。
• DRUG COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING THROMBOSIS OR EMBOLISM
  申请人：OHTA Toshiharu

  公开号：US20090281074A1

  公开（公告）日：2009-11-12

  Drug compositions containing a substituted diamine compound represented by formula (1): Q 1 -Q 2 -r-N(R 1 )-Q 3 -N(R 2 )  (1) wherein Q 3 represents the following group wherein Q 5 represents an alkylene group having 4 carbon atoms, R 3 represents a hydrogen atom, and R 4 represents a 3-6 membered heterocyclic group which may be substituted; are useful for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  含有以下式子（1）所代表的取代二胺化合物的药物组合物： Q1-Q2-r-N（R1）-Q3-N（R2）  （1） 其中，Q3代表以下基团： 其中，Q5代表具有4个碳原子的烷基基团，R3代表氢原子，R4代表可取代的3-6环杂环基团； 该药物组合物对于预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、人工瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征（SIRS）、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成或采血时的血凝。
• METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES
  申请人：Ohta Toshiharu

  公开号：US20100099660A1

  公开（公告）日：2010-04-22

  A method for treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing is provided. The method includes administration of an effective amount of a compound represented by formula (1):

  提供了一种治疗脑梗塞、脑栓塞、心肌梗死、心绞痛、肺梗塞、肺栓塞、布尔格病、深静脉血栓形成、弥散性血管内凝血综合征、人工瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、多器官功能障碍综合征（MODS）、体外循环期间的血栓形成或采血时的血液凝固的方法。该方法包括给予化合物（1）式所代表的有效量。
• Diamine derivatives
  申请人：Ohta Toshiharu

  公开号：US20060252837A1

  公开（公告）日：2006-11-09

  A compound represented by formula (1): Q 1 -Q 2 -T o -N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 ( 1 ) [wherein R 1 and R 2 are hydrogen atoms or the like; Q 1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q 2 is a single bond or the like; Q 3 represents the following group: (wherein Q 5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T 0 and T 1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

  化合物的化学式为(1): Q1-Q2-To-N(R1)-Q3-N(R2)-T1-Q4(1) [其中，R1和R2是氢原子或类似物; Q1是饱和或不饱和的、5-或6-成员的环烃基，可以被取代，或类似物; Q2是单键或类似物; Q3表示以下基团: (其中，Q5是具有1至8个碳原子的烷基或类似物); T0和T1是羰基基团或类似物]，其盐、溶剂化物或N-氧化物。该化合物可用作预防和/或治疗脑梗死、脑栓塞、心肌梗死、心绞痛、肺梗死、肺栓塞、布氏病、深静脉血栓形成、弥散性血管内凝血综合征、人工瓣膜或关节置换后的血栓形成、血管成形术后的血栓形成和再闭塞、全身性炎症反应综合征(SIRS)、多器官功能障碍综合征(MODS)、体外循环期间的血栓形成或采血时的血液凝结。